Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Jian-Gui He"'
Autor:
Da-ya Yang, Xin He, Hui-wei Liang, Shao-zhao Zhang, Xiang-bin Zhong, Chu-fan Luo, Zhi-min Du, Jian-gui He, Xiao-dong Zhuang, Xin-xue Liao
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-8 (2019)
Abstract Background The cardiovascular (CV) safety in terms of heart failure among different classes of treatment remains largely unknown. We sought to assess the comparative effect of these agents on heart failure outcomes. Methods This study was re
Externí odkaz:
https://doaj.org/article/86c68e82a0be413d8aeff7eb7c9b573a
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-10 (2018)
Abstract Background Cardiovascular (CV) safety of one anti-diabetic medication over another remains partially delineated. We sought to assess the comparative effect on CV outcomes among novel anti-diabetic agents. Methods This study was registered wi
Externí odkaz:
https://doaj.org/article/a23b181aca4b4db9bf8f0fd743f38917
Autor:
Da-Ya Yang, He, Xin, Liang, Hui-Wei, Shao-Zhao Zhang, Zhong, Xiang-Bin, Chu-Fan Luo, Du, Zhi-Min, Jian-Gui He, Zhuang, Xiao-Dong, Xin-Xue Liao
Additional file 7: Figure S3. Sensitivity analysis after excluding studies with a follow-up period of fewer than 48 weeks.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a5f750bde6e106d0eb003ecc5100abd
Additional file 1: S1. Protocol. S2. Search strategy. S3. Novel drugs approved by FDA or European Medicines Agency. S4. Flow chart of the study selection process. S5. Studies characteristic of the included studies. S6. Outcomes of interest in each st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e32d8f34efbba6b17439b57238f381
Publikováno v:
Biochemical and Biophysical Research Communications. 389:138-144
Angiotensin-(1-7) [ANG-(1-7)] has been reported to attenuate neointimal formation after vascular injury and stent implantation in rats, but the mechanism remains mostly unresolved. Interestingly, the levels of circulating transforming growth factor-b
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 36:925-932
SUMMARY 1It has been demonstrated that epigallocatechin-3-gallate (EGCG) inhibits cardiac hypertrophy through its antihypertensive and anti-oxidant effects. However, the underlying molecular mechanism is not clear. 2In the present study, we tested th
Publikováno v:
Journal of Cardiovascular Diseases & Diagnosis.
We describe a case of 47-year-old man who suffered a sinus node reentrant tachycardia and a typical counterclockwise cavotricuspid isthmus dependent atrial flutter. The dynamic isopotential mapping with non-contact mapping system showed that source a
Autor:
Su-Hua, Wu, Xiao-Xiong, Lin, Yun-Jiu, Cheng, Yu-Gang, Dong, An-Li, Tang, Jian-Gui, He, Jun, Liu, Hong, Ma
Publikováno v:
Journal of the American College of Cardiology. 61(22)
Publikováno v:
Zhonghua xin xue guan bing za zhi. 38(6)
To explore the effects of Angiotensin (ANG)-(1-7) on postangioplasty fibrotic remodeling and the involvement of TGF-beta/Smad signaling pathway in this process.Thirty two healthy New Zealand white rabbits were randomly divided into 4 groups: sham gro
Autor:
Lin Chen, Jing-Feng Wang, Liming You, Jing-Hua Chen, Jun Yan, Bailing Liu, Shangyi Jin, Jian-Gui He, Jingjing Zhou
Publikováno v:
Patient education and counseling. 85(3)
Objective To explore illness perception (IP) and its predictors among Chinese patients with myocardial infarction (MI). Methods The revised Illness Perception Questionnaire (IPQ-R) was used in the present study. A cross-sectional, descriptive design